🇺🇸 RCUS — Arcus Biosciences, Inc.

Salud Compra fuerte
← Volver

Precio actual

18,91 USD

Máx. histórico

48,47

1806 días

Caída desde máximo

-60,99%

Rango 52 semanas

17,43 – 31,74

Variación hoy

+5,94%

Cierre anterior

17,85

Rango de hoy

18,05 – 18,98

Volumen hoy

1.935.563

Peor caída histórica

-85,83%

23/11/2021 → 04/04/2025

Aún sin recuperar

Volatilidad anualizada ⓘ

75,63%

Información
Nombre completo
Arcus Biosciences, Inc.
Divisa
USD
Mercado
NYSE
Sector
Salud
Industria
Biotechnology
Empleados
601
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
41,00 USD (puede no estar actualizado)
Primera cotización
15/03/2018
Precio actualizado
hace 23 horas
Sobre la empresa

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases; and Bristol-Myers Squibb Company to develop a novel treatment regimen that delivers tumor control in kidney cancer. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
26/06/2018 14,57 14,80 14,19 14,22 -2,34% 4,19% 72.200
25/06/2018 15,51 15,51 14,15 14,56 -5,76% 8,77% 175.200
22/06/2018 16,08 16,12 15,08 15,45 -3,56% 6,47% 1.201.900
21/06/2018 16,34 16,50 15,91 16,02 -1,48% 3,61% 106.700
20/06/2018 16,89 17,18 16,12 16,26 -4,07% 6,28% 124.400
19/06/2018 15,85 17,05 15,76 16,95 +5,94% 8,17% 289.200
18/06/2018 16,14 16,20 15,83 16,00 -0,12% 2,29% 127.400
15/06/2018 15,99 16,46 15,51 16,02 -0,25% 5,94% 433.900
14/06/2018 16,45 16,89 16,06 16,06 -1,89% 5,02% 187.700
13/06/2018 16,38 16,57 16,10 16,37 -0,24% 2,87% 203.000
12/06/2018 16,05 16,95 16,05 16,41 +1,80% 5,61% 123.300
11/06/2018 17,25 17,50 15,96 16,12 -4,90% 8,93% 182.000
08/06/2018 16,23 17,20 16,21 16,95 +4,12% 6,11% 177.900
07/06/2018 15,95 16,40 15,68 16,28 +2,01% 4,55% 126.900
06/06/2018 15,87 16,44 15,54 15,96 +0,69% 5,67% 121.200
05/06/2018 16,14 16,48 15,26 15,85 -1,86% 7,54% 198.100
04/06/2018 15,52 16,37 15,20 16,15 +4,13% 7,54% 144.000
01/06/2018 16,07 16,11 15,51 15,51 -2,64% 3,73% 69.700
31/05/2018 15,86 16,28 15,53 15,93 +0,63% 4,73% 179.000
30/05/2018 16,13 16,35 15,78 15,83 -1,00% 3,50% 63.900
29/05/2018 16,20 16,40 15,75 15,99 -1,60% 3,99% 78.200
25/05/2018 16,20 17,14 16,04 16,25 +0,43% 6,79% 171.900
24/05/2018 15,85 16,38 15,85 16,18 +1,76% 3,37% 42.200
23/05/2018 16,58 16,81 15,51 15,90 -4,85% 7,84% 124.500
22/05/2018 16,07 16,93 15,91 16,71 +4,57% 6,35% 66.000
21/05/2018 16,15 16,33 15,86 15,98 -0,87% 2,91% 38.100
18/05/2018 16,28 16,51 15,91 16,12 -0,98% 3,69% 27.200
17/05/2018 16,31 16,70 15,76 16,28 +0,56% 5,76% 49.000
16/05/2018 16,19 17,09 15,47 16,19 +0,37% 10,04% 142.800
15/05/2018 15,65 16,28 15,31 16,13 +2,80% 6,23% 52.500